|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:antidote
|
gptkb:flumazenil
|
|
gptkbp:approvedBy
|
1977
|
|
gptkbp:ATCCode
|
N05BA06
|
|
gptkbp:bioavailability
|
90% (oral)
|
|
gptkbp:brand
|
gptkb:Ativan
|
|
gptkbp:CASNumber
|
846-49-1
|
|
gptkbp:category
|
benzodiazepine
sedative
anticonvulsant
muscle relaxant
hypnotic
|
|
gptkbp:chemicalClass
|
1,4-benzodiazepine
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
hypersensitivity to benzodiazepines
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
10-20 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C15H10Cl2N2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
lorazepam
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
confusion
hypotension
somnolence
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
85%–90%
|
|
gptkbp:riskOfDependence
|
yes
|
|
gptkbp:riskOfWithdrawal
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
confusion
dizziness
drowsiness
respiratory depression
weakness
|
|
gptkbp:synonym
|
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:usedFor
|
status epilepticus
insomnia
anxiety disorders
alcohol withdrawal
preoperative sedation
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:benzodiazepines
gptkb:CNS_depressants
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|